"Psoriatic Arthritis (PsA) Market Market– Industry Tren ds and Forecast to 2029

Global Psoriatic Arthritis (PsA) Market, By Types (Symmetric PsA, Asymmetric PsA, Spondylitis PsA Psoriatic Arthritis Mutilans, Distal Interphalangeal Predominant PsA), Treatment (Medication, Surgery, Others), Diagnosis (X-rays, Magnetic Resonance Imaging (MRI), Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Data Bridge Market Research analyses that the psoriatic arthritis (PsA) market was valued at USD 11.26 billion in 2021 and is expected to reach USD 23.10 billion by 2029, registering a CAGR of 9.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Access Full 350 Pages PDF Report @

https://www.databridgemarketresearch.com/reports/global-psoriatic-arthritis-psa-market

Psoriatic arthritis (PsA) is an inflammatory condition that affects the joints and the areas where tendons and ligaments link to bone. Psoriatic arthritis doesn't have a cure. Controlling inflammation in affected joints to avoid joint pain and impairment and controlling skin involvement are the main goals of treatment. Prescription pharmaceuticals known as disease-modifying antirheumatic drugs are one of the most common treatments (DMARDs). For those with mild psoriatic arthritis, nonsteroidal anti-inflammatory drugs (NSAIDs) can help alleviate pain and inflammation. Artificial metal and plastic joints can be used to replace some of the joints that have been significantly destroyed by psoriatic arthritis.

**Segments**

- Drug Class: The Psoriatic Arthritis (PsA) market can be segmented based on the drug class, which includes Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), and Biologics. NSAIDs are commonly used for pain relief and reducing inflammation in PsA patients. DMARDs work by modifying the underlying disease process. Biologics, on the other hand, are specifically designed to target different proteins in the immune system to reduce inflammation and joint damage.

- Distribution Channel: The market for Psoriatic Arthritis can also be segmented based on the distribution channels, including Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies are a key channel for patients who require immediate medication and treatment. Retail pharmacies cater to the broader market and are accessible to patients for regular medication refills. Online pharmacies offer convenience and accessibility to patients who prefer ordering medications from the comfort of their homes.

- Region: Geographically, the Psoriatic Arthritis market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe dominate the market due to the high prevalence of PsA, advanced healthcare infrastructure, and increasing awareness about the disease. The Asia Pacific region is witnessing significant growth attributed to the rising incidence of PsA, improving healthcare facilities, and increasing focus on research and development in the pharmaceutical sector.

**Market Players**

- AbbVie Inc.: AbbVie is a leading player in the Psoriatic Arthritis market with its blockbuster drug, Humira (adalimumab), one of the most prescribed biologics for PsA. The company continues to invest in research and development to introduce innovative treatments for Psoriatic Arthritis patients.

- Amgen Inc.: Amgen is another key player in the Psoriatic Arthritis market, offering biologic drugs such as Enbrel (etanercept)AbbVie Inc. and Amgen Inc. are significant players in the Psoriatic Arthritis (PsA) market, each contributing unique offerings to cater to the growing demand for effective treatments. AbbVie's flagship product, Humira (adalimumab), has established itself as a cornerstone in PsA treatment regimens, thanks to its efficacy in reducing inflammation and improving joint symptoms in patients. The company's strong focus on research and development ensures a steady stream of innovative therapies to address the evolving needs of PsA patients. AbbVie's commitment to advancing the field of PsA therapeutics through investment in clinical studies and collaborations with healthcare providers highlights its dedication to enhancing patient outcomes in the PsA market.

On the other hand, Amgen Inc. plays a pivotal role in the PsA market with its biologic drug Enbrel (etanercept), which has been pivotal in providing relief to PsA patients by targeting specific proteins in the immune system responsible for inflammation. Amgen's contribution to the PsA market extends beyond product offerings, as the company actively engages in initiatives aimed at raising awareness about PsA, fostering collaborations with healthcare professionals, and supporting patient advocacy groups. By leveraging its expertise in biologics and commitment to patient-centric care, Amgen continues to shape the landscape of PsA treatment through innovation and strategic partnerships within the healthcare ecosystem.

The Psoriatic Arthritis market is characterized by a diverse range of drug classes, distribution channels, and regional dynamics that collectively influence market growth and competitive dynamics. The segmentation based on drug class underscores the importance of tailored treatment approaches for PsA patients, where NSAIDs, DMARDs, and Biologics play distinct roles in managing symptoms and disease progression. The prevalence of PsA across different regions, such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, underscores the global impact of the disease and the need for targeted interventions that consider regional variations in healthcare infrastructure and patient demographics.

**Segments**

- **Global Psoriatic Arthritis (PsA) Market, By Types:** Symmetric PsA, Asymmetric PsA, Spondylitis PsA, Psoriatic Arthritis Mutilans, Distal Interphalangeal Predominant PsA.
- **Treatment:** Medication, Surgery, Others.
- **Diagnosis:** X-rays, Magnetic Resonance Imaging (MRI), Others.
- **Route of Administration:** Oral, Topical, Others.
- **End-Users:** Hospitals, Specialty Clinics, Homecare, Others.
- **Distribution Channel:** Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others

Psoriatic Arthritis (PsA) is a chronic autoimmune disease that affects the skin and joints, leading to inflammation, pain, and stiffness. The global market for PsA is witnessing substantial growth, driven by factors such as increasing prevalence of the disease, advancements in treatment options, and growing awareness among healthcare professionals and patients. The segmentation of the market based on different types of PsA allows for a more targeted and personalized treatment approach to cater to the diverse needs of patients. Symmetric PsA, Asymmetric PsA, Spondylitis PsA, Psoriatic Arthritis Mutilans, and Distal Interphalangeal Predominant PsA represent distinct manifestations of the disease, each requiring specific interventions tailored to their unique characteristics.

In terms of treatment, the market offers a range of options including medications

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Global Psoriatic Arthritis (PsA) Market Landscape

Part 04: Global Psoriatic Arthritis (PsA) Market Sizing

Part 05: Global Psoriatic Arthritis (PsA) Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Psoriatic Arthritis (PsA) Key Benefits over Global Competitors:

• The report provides a qualitative and quantitative analysis of the Psoriatic Arthritis (PsA) Market trends, forecasts, and market size to determine new opportunities.
• Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.
• Top impacting factors & major investment pockets are highlighted in the research.
• The major countries in each region are analyzed and their revenue contribution is mentioned.
• The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients

Browse Trending Reports:

Glucaric Acid Market
Coffee And Tea Processing Equipment Market
Nano Bioreactor Market
Shock Sensor Market
Metal Injection Molding Mim Market
Medical Billing Software Market
Feed Anticoccidials Market
Electric Motorcycles Market
Industrial Denox Systems Market
Seed Treatment Biofertilizers Market
Hemostasis Diagnostics Market
Poultry Feed Yeast Market
Functional Printing Market
Coagulation Reagents Market
Dandy Walker Treatment Market
Influenza Diagnostics Market
Pediatric Congenital Athymia Treatment Market
Grain Silos And Storage System Market
Heat Shrink Tubing Market
Structural Insulated Panel Market
Micro Flute Paper Market
Mens Grooming Products Market
Near Infrared Nir Portable Spectrometer Market
Mortuary Equipment Market
Medical Waste Disposal Services Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"